Subtype
Endometrial Neoplasm
CI-CAN-00007648Explore in graph →
Non-malignant400 active trials4 approved drugs28 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007648Explore in graph →
Clinical trials
1,340 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | GenmabINDUSTRY | 2 | Jun 1, 2026 | clinicaltrials |
| NCT06680739 | Single cEll pRofiling PErsistaNce To ImmuNothErapy(SERPENTINE) | recruiting | Phase 2 | 60 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) |
| active not recruiting |
| Phase 1 / Phase 2 |
| 540 |
| Eli Lilly and CompanyINDUSTRY |
| 6 |
| May 29, 2026 |
| clinicaltrials |
| NCT06851663 | Trop2-targeted immunoPET Imaging of Solid Tumors | recruiting | Phase 2 / Phase 3 | 400 | RenJi HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07612891 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor | recruiting | Phase 1 / Phase 2 | 201 | Shenzhen Ionova Life Sciences Co., Ltd.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT02755844 | Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients(ENDOLA) | completed | Phase 1 / Phase 2 | 35 | Hospices Civils de LyonOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT03008408 | A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma | active not recruiting | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07605247 | Tirzepatide in the Treatment of Endometrial Cancer(TREAT-EC) | not yet recruiting | Phase 2 | 30 | Rutgers, The State University of New JerseyOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT05761951 | Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05255653 | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features(RAINBO) | recruiting | Phase 2 / Phase 3 | 1,615 | Leiden University Medical CenterOTHER | 4 | May 15, 2026 | clinicaltrials |
| NCT05979610 | Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies(Reiki-Brachy) | recruiting | Phase 2 | 70 | University of UtahOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06023862 | A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)(DOVE) | recruiting | Phase 2 | 198 | Yonsei UniversityOTHER | 7 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT06180733 | Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer(PAM-II) | active not recruiting | Phase 2 | 12 | University Medical Center GroningenOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT01068249 | Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06532539 | Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma | recruiting | Phase 2 | 30 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03682289 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 83 | Rahul AggarwalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07146919 | AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer(ANGELICA) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Leon BerardOTHER | 0 | Apr 23, 2026 | clinicaltrials |
| NCT02874430 | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer | terminated | Phase 2 | 29 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05559879 | Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma | recruiting | Phase 1 / Phase 2 | 37 | University of Alabama at BirminghamOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT01164150 | Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06 | terminated | Phase 2 | 92 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT01244789 | Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer | active not recruiting | Phase 2 | 244 | Danish Gynecological Cancer GroupNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03694262 | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)(EndoBARR) | completed | Phase 2 | 30 | Medical College of WisconsinOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07522697 | Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4(MITO END-4) | not yet recruiting | Phase 2 | 48 | National Cancer Institute, NaplesOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06253494 | Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer | recruiting | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07516210 | Adaptive Radiotherapy for Safe Hypofractionation(ART-Hypo) | not yet recruiting | Phase 2 | 264 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04486352 | A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer(EndoMAP) | recruiting | Phase 1 / Phase 2 | 148 | Alliance Foundation Trials, LLC.OTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07377734 | Intrauterine Injection of Type III Collage in FST of EC/AEH(2026ColECFerSp) | recruiting | Phase 2 | 30 | Wang JianliuOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05036681 | A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma | terminated | Phase 2 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05870761 | Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma | active not recruiting | Phase 2 | 8 | Casey CosgroveOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies(ERADIC8) | recruiting | Phase 1 / Phase 2 | 120 | 858 Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors(BetaBart) | recruiting | Phase 1 / Phase 2 | 61 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07276360 | Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda(HypoRTCx-UG) | recruiting | Phase 2 | 278 | Uganda Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05112991 | Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer | recruiting | Phase 2 | 108 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03617679 | Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer | completed | Phase 2 | 79 | University of Colorado, DenverOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT04008797 | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 301 | Eisai Inc.INDUSTRY | 10 | Mar 24, 2026 | clinicaltrials |
| NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | completed | Phase 2 | 163 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 19, 2026 | clinicaltrials |
| NCT04814108 | A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma | completed | Phase 2 | 92 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT07319429 | Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification(FEMUS) | recruiting | Phase 2 / Phase 3 | 260 | Fudan UniversityOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05824481 | Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer | active not recruiting | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04393285 | Abemaciclib and Letrozole to Treat Endometrial Cancer | active not recruiting | Phase 2 | 53 | Gynecologic Oncology GroupNETWORK | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 626 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 6, 2026 | clinicaltrials |
| NCT06369155 | Azenosertib in Uterine Serous Carcinoma: Biomarker Study | recruiting | Phase 2 | 25 | Joyce Liu, MDOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT04781088 | Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 | 38 | Floor Backes, MDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06710847 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors(SYLVER) | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 7 | Feb 2, 2026 | clinicaltrials |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07369986 | Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer(IMMUNE-SAVE) | not yet recruiting | Phase 2 | 30 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 0 | Jan 27, 2026 | clinicaltrials |
| NCT04576104 | Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer | active not recruiting | Phase 2 | 51 | Northwestern UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07054567 | A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer | recruiting | Phase 2 | 96 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 1, 2026source: clinicaltrials